Filtered By:
Specialty: Drugs & Pharmacology
Condition: Liver Disease
This page shows you your search results in order of date.
Order by Relevance | Date
Total 58 results found since Jan 2013.
Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin
This article aims to provide the most updated information on targeting the liver with ASO and siRNA drugs. The generated knowledge may stimulate further investigations in this growing field of new therapeutic entities for the treatment of some human systemic diseases, which currently have no or limited options for treatment.PMID:37696583 | DOI:10.1124/pharmrev.123.000815
Source: Pharmacological Reviews - September 11, 2023 Category: Drugs & Pharmacology Authors: Anagha Gogate Jordyn Belcourt Milan Shah Alicia Zongxun Wang Alexis Frankel Holly Kolmel Matthew Chalon Prajith Stephen Aarush Kolli Sherouk M Tawfik Jing Jin Raman Bahal Theodore P Rasmussen Jose E Manautou Xiao-Bo Zhong Source Type: research
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease
This article describes the role of misfolded proteins and protein aggregates in disease and options for therapeutic approaches. The RNAi mechanism is discussed, along with how the siRNA therapeutic fazirsiran for the treatment of AATD was developed. We also describe the implications of siRNA therapeutics in extrahepatic diseases.EXPERT OPINION: Using RNAi as a therapeutic approach is well suited to treat disease in conditions where an excess of a protein or the effect of an abnormal mutated protein causes disease. The results observed for the first few siRNA therapeutics that were approved or are in development provide an ...
Source: Expert Opinion on Investigational Drugs - July 20, 2023 Category: Drugs & Pharmacology Authors: Pavel Strnad Javier San Martin Source Type: research
RNAi Therapeutics for Diseases Involving Protein Aggregation: Fazirsiran for Alpha-1 Antitrypsin Deficiency-associated Liver Disease
This article describes the role of misfolded proteins and protein aggregates in disease, and options for therapeutic approaches. The RNAi mechanism is discussed, along with how the siRNA therapeutic fazirsiran for the treatment of AATD was developed. We also describe implications of siRNA therapeutics in extrahepatic diseases.EXPERT OPINION: Using RNAi as a therapeutic approach is well suited to treat disease in conditions where an excess of a protein or the effect of an abnormal mutated protein causes disease. The results observed for the first few siRNA therapeutics that were approved or are in development provide an imp...
Source: Expert Opinion on Investigational Drugs - July 20, 2023 Category: Drugs & Pharmacology Authors: Pavel Strnad Javier San Martin Source Type: research
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease
This article describes the role of misfolded proteins and protein aggregates in disease and options for therapeutic approaches. The RNAi mechanism is discussed, along with how the siRNA therapeutic fazirsiran for the treatment of AATD was developed. We also describe the implications of siRNA therapeutics in extrahepatic diseases.EXPERT OPINION: Using RNAi as a therapeutic approach is well suited to treat disease in conditions where an excess of a protein or the effect of an abnormal mutated protein causes disease. The results observed for the first few siRNA therapeutics that were approved or are in development provide an ...
Source: Expert Opinion on Investigational Drugs - July 20, 2023 Category: Drugs & Pharmacology Authors: Pavel Strnad Javier San Martin Source Type: research
RNAi Therapeutics for Diseases Involving Protein Aggregation: Fazirsiran for Alpha-1 Antitrypsin Deficiency-associated Liver Disease
This article describes the role of misfolded proteins and protein aggregates in disease, and options for therapeutic approaches. The RNAi mechanism is discussed, along with how the siRNA therapeutic fazirsiran for the treatment of AATD was developed. We also describe implications of siRNA therapeutics in extrahepatic diseases.EXPERT OPINION: Using RNAi as a therapeutic approach is well suited to treat disease in conditions where an excess of a protein or the effect of an abnormal mutated protein causes disease. The results observed for the first few siRNA therapeutics that were approved or are in development provide an imp...
Source: Expert Opinion on Investigational Drugs - July 20, 2023 Category: Drugs & Pharmacology Authors: Pavel Strnad Javier San Martin Source Type: research
RNAi therapeutics for diseases involving protein aggregation: fazirsiran for alpha-1 antitrypsin deficiency-associated liver disease
This article describes the role of misfolded proteins and protein aggregates in disease and options for therapeutic approaches. The RNAi mechanism is discussed, along with how the siRNA therapeutic fazirsiran for the treatment of AATD was developed. We also describe the implications of siRNA therapeutics in extrahepatic diseases.EXPERT OPINION: Using RNAi as a therapeutic approach is well suited to treat disease in conditions where an excess of a protein or the effect of an abnormal mutated protein causes disease. The results observed for the first few siRNA therapeutics that were approved or are in development provide an ...
Source: Expert Opinion on Investigational Drugs - July 20, 2023 Category: Drugs & Pharmacology Authors: Pavel Strnad Javier San Martin Source Type: research
Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway
Biomed Pharmacother. 2023 Jul 5;165:115113. doi: 10.1016/j.biopha.2023.115113. Online ahead of print.ABSTRACTNonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases with limited treatment options. Moreover, its prevalence is doubled in type 2 diabetes mellitus (T2DM). Kaempferol (KAP) is a flavonoid compound that has been suggested to have beneficial effects on NAFLD, but studies on the mechanism are lacking, especially in the diabetic state. Herein, we investigated the effect of KAP on NAFLD associated with T2DM and its underlying mechanism in vitro and in vivo. The results of in vitro studies in...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 7, 2023 Category: Drugs & Pharmacology Authors: Na Li Lin Yin Jiamin Shang Meidai Liang Zhaoyu Liu Haiguang Yang Guifen Qiang Guanhua Du Xiuying Yang Source Type: research
Induction of autophagy via the PI3K/Akt/mTOR signaling pathway by Pueraria flavonoids improves non-alcoholic fatty liver disease in obese mice
Biomed Pharmacother. 2022 Nov 13;157:114005. doi: 10.1016/j.biopha.2022.114005. Online ahead of print.ABSTRACTNon-alcoholic fatty liver disease (NAFLD) is the most common among lipid metabolism disorders. Autophagy plays an important role in lipid metabolism in NAFLD. Pueraria flavonoids, the main active ingredients of Pueraria lobata, exert antioxidant and anti-inflammatory effects. Herein, we report the potential lipid-lowering and anti-inflammatory effects of Pueraria flavonoids on NAFLD induced by a high-fat diet. In vivo and in vitro experiments showed that Pueraria flavonoids reduced intracellular lipid deposition by...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - November 16, 2022 Category: Drugs & Pharmacology Authors: Chunbin Sun Jin Zhang Jiong Hou Menglin Hui Hualong Qi Tong Lei Xiaoshuang Zhang Luxi Zhao Hongwu Du Source Type: research
Effects of Sedi Herba (Sedum sarmentosum) on attenuating cholestasis by the activation of the farnesoid x receptor (FXR)-mediated signaling
This study aimed to clarify the anti-cholestatic efficacy and the mechanism of S. sarmentosum ethyl acetate extract (SDEAE), as well as to screen the potential compounds with FXR activation. SDEAE effectively ameliorated ANIT-induced cholestasis in rats, as evidenced by the ameliorative histopathology of the liver and the significant decrease in biochemical markers (ALT, AST, ALP, GGT, TBIL, DBIL and TBA). The analysis of bile acid profile by LC-MS indicated that SDEAE decreased the toxic bile acid levels (TCA, TMCA and CA). Western blotting indicated that SDEAE activated FXR-associated pathway, thereby upregulating FXR, S...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 22, 2022 Category: Drugs & Pharmacology Authors: Zhenxiu Liu Die Liu Mingyun Chen Wei Zong Xiaoran Zhou Fancheng Meng Yunbin Jiang Min Chen Zhihua Liao Guowei Wang Source Type: research
Baicalin improved hepatic injury of NASH by regulating NRF2/HO-1/NRLP3 pathway
This study indicates that baicalin is able to attenuate hepatic cell pyroptosis in vivo and in vitro in the case of NASH by regulating the NRF2/HO-1/NRLP3 pathway.PMID:36184988 | DOI:10.1016/j.ejphar.2022.175270
Source: European Journal of Pharmacology - October 3, 2022 Category: Drugs & Pharmacology Authors: Huilian Shi Fei Qiao Weiting Lu Kaiyue Huang Yuanyuan Wen Lifang Ye Yuanyuan Chen Source Type: research
